Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of camrelizumab plus apatinib for malignant mesothelioma
ChiCTR2300076546Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in mesothelioma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ChiCTR2300076546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076546.